Navigation Links
Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference
Date:5/7/2013

sts the company may develop to optimize cancer treatment and the Company's ability to launch new tests in new markets and expand internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners. 


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Real Time Genomics and Knome Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS100 System
2. Neogen launches comprehensive cattle genomic test
3. Real Time Genomics and J. Craig Venter Institute Embark on Strategic Research Initiative
4. Nimbix and Convey Partner for “The Accelerated Genomics Cloud” (TAGC) Promotion
5. Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
6. Real Time Genomics and Omicia Partner on a Platform for Integrated Genomic Analysis for Childhood Disease
7. Venter Institute-Led Team Recovers and Sequences Genome of Periodontal Pathogen from Biofilm in Hospital Sink using Single-Cell Genomics
8. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
9. Squished bug genomics: Insect goo aids biodiversity research
10. Ingenuity Systems IPA Provides Researchers with Genomic Insights Suggesting that Physical Activity Does Not Slow Muscle Aging
11. BGI-Shenzhen Completes Acquisition of Complete Genomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DIEGO and TORONTO , ... APTO ; TSX: APS), a clinical-stage company developing new ... announced that the U.S. Food and Drug Administration (FDA) ... for the treatment of acute myeloid leukemia (AML). APTO-253, ... company,s lead product candidate in a Phase Ib clinical ...
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... Pa. , June 2, 2015   ... be attending the BIO Exhibition 2015 in ... Exhibition, the world,s largest biotechnology gathering, allows influential ... high-level executives, where they can evaluate emerging technologies ... significant eClinical expertise in the design, implementation and ...
(Date:6/2/2015)... Mass. , June 2, 2015 /PRNewswire/ ... a biotechnology company focused on discovering and ... of dermatology and ophthalmology, today announced that Dr. ... Officer, will present at the 23 rd ... six-day world congress will include in-depth presentations ...
Breaking Biology Technology:Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4
... CHARLOTTESVILLE, Virginia, June 23 ... targeting epilepsy, has shown,positive results in the Kainic ... existing drug that Biovista repositioned in epilepsy, exhibits,both ... induced a statistically significant decrease of epileptic activity ...
... to Nearly $4 Million , , BETHPAGE, N.Y., ... largest private supporter of pancreatic cancer research, today announced its ... six leading research centers for early diagnostic tests and better ... , Lustgarten is expected to award nearly $4 million ...
... , SEATTLE, June 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... a division of Wyeth (NYSE: WYE ), ... collaboration agreement with Trubion to extend the research period ... Under the terms of the research period extension, Wyeth,s ...
Cached Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy 2The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... researchers in Switzerland has published a study appearing in the ... that shows how the cornea uses stem cells to ... everyday wear and tear on the cornea is repaired from ... serious repair jobs require the involvement of other stem cells ...
... (NorthShore) and Northwestern University have discovered that fiber optic ... blood levels in the colonic lining (mucosa) in humans, ... cancer. The study appears in the October ... of the American Gastroenterological Association (AGA) Institute. ...
... is a primary concern for agricultural producers in the United ... effort to maintain a profitable crop output. , ... while it is known that using nitrogen fertilizers can increase ... following cash crops have been unknown. Researchers found ...
Cached Biology News:The role of stem cells in renewing the cornea 2Breakthrough optical technology to assess colon cancer risk, accuracy 2Breakthrough optical technology to assess colon cancer risk, accuracy 3Nitrogen applied 2
...
A component of the Acridinium protein labeling kit....
... detection system holds 48 x 0.2 ml tubes, ... LEDs independently excites fluorescence (470-500 nm) for each ... emitted light (523-543 nm and 540-700 nm). The ... whose Peltier heat pumps provide superb thermal performance. ...
... Automated instrument designed to hold up to ... The robust and easy to use design ensures ... with regular cyclic stretching or compression. This unit ... of the strain to produce 64 unique strain ...
Biology Products: